Opioids have been shown to influence the immune system and to promote the expression of pro-inflammatory cytokines in the central nervous system. However, recent data have shown that activation of opioid receptors increases the expression and release of the neuroprotective chemokine CCL5 from astrocytes in vitro. To further define the interaction between CCL5 and inflammation in response to opioids, we have examined the effect of chronic morphine and morphine withdrawal on the in vivo expression of CCL5 as well as of pro-inflammatory cytokines interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). Rats undergoing a chronic morphine paradigm (10 mg/kg increasing to 30 mg/kg, twice a day for 5 days) showed a twofold increase of CCL5 protein and mRNA within the cortex and striatum. No changes were observed in the levels of IL-1b and TNF-a. Naltrexone blocked the effect of morphine. A chronic morphine paradigm with no escalating doses (10 mg/kg, twice a day) did not alter CCL5 levels compared to saline-treated animals. On the contrary, rats undergoing spontaneous morphine withdrawal exhibited lower levels of CCL5 within the cortex as well as increased levels of pro-inflammatory cytokines and Iba-1 positive cells than saline-treated rats. Overall, these data suggest that morphine withdrawal may promote cytokines and other inflammatory responses that have the potential of exacerbating neuronal damage.
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Introduction
The adverse effects of opioids such as heroin and morphine on the adaptive and innate immune systems have been recognized [reviewed in Hutchinson et al. (2011 ), Roy et al. (2011 . Less is known about opioid-induced changes in central nervous system (CNS) immune responses. Morphine has been shown to promote the expression of pro-inflammatory cytokines and chemokines in the CNS (Johnston et al., 2004; Schwarz et al., 2013) . Cytokines and chemokines are soluble polypeptides that were discovered for their ability to modulate immune responses as well as cell migration. In the CNS, these polypeptides are synthetized and released mostly by glial cells, which are considered the immune competent cells of the CNS as well as crucial components of synaptic plasticity (Huang et al., 2000; Ransohoff and Brown, 2012) . Therefore, opioids, through cytokines and chemokines, could contribute to pathological states or participate in the maintenance of healthy neurons. On the other hand, morphine-mediated increase of cytokines/chemokines appears to be more pronounced in brain areas that participate in the neuronal network involved in opiate abuse/reward, including the nucleus accumbens (Schwarz et al., 2011) . Moreover, in recent years, several lines of independent investigations have shown that the immune system may play a role in the behavior outcome following opioid administration [reviewed in Coller and Hutchinson (2012) ]. Thus, re-evaluating whether a given cytokine or chemokine is enhanced in response to an inflammatory pathological state or to activation of a brain circuitry involved with drug abuse is crucial for a better understanding of opioid action and immune responses.
There are a number of cytokines and chemokines in the brain (Cartier et al., 2005) . Chemokines and their receptors are often involved with the progression of neurodegenerative diseases. However, some of these molecules exhibit a profile similar to that of neuromodulators (Adler and Rogers, 2005; Rostene et al., 2007) or behave like neurotrophic factors. For instance the chemokine CCL5, formerly known as regulated on activation normal T-cell expressed and secreted (RANTES), was discovered for its ability to attract and activate mononuclear phagocytes, as well as several other leukocyte types, to sites of inflammation/injury. However, CCL5's main receptor CCR5 is expressed in the CNS (Avdoshina et al.,
